Reading Time: 1 minute
The Amgen stock (NASDAQ: AMGN) is, in my view, a defensive biotech giant with remarkable stability. The company is represented in the Dow Jones Industrial Average, S&P 500, and Nasdaq 100 and has an exceptionally robust operational base: 14 blockbuster drugs, each generating over $1 billion in annual revenue, provide predictable cash flows and broad diversification. What's particularly impressive is the capital discipline: For 15 years, the dividend has been increased every year. This is a strong signal of reliability and shareholder focus....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
